Assessment of Orphan Drugs in Germany
Author Information
Author(s): Philip Kranz, Natalie McGauran, Can Ünal, Thomas Kaiser
Primary Institution: Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany
Hypothesis
Has the increase in orphan drug approvals led to improvements in patient-relevant outcomes in Germany?
Conclusion
Many orphan drugs approved in the EU lack proof of added benefit in improving patient-relevant outcomes due to evidence gaps.
Supporting Evidence
- Eighty-nine orphan drugs were evaluated in 175 research questions.
- In regular HTAs, no proof of added benefit was shown in fifty-four percent of the questions.
- Established treatments were available for fifty-eight percent of the questions analyzed.
Takeaway
This study looked at orphan drugs in Germany and found that many of them don't actually help patients as much as we thought.
Methodology
The study analyzed health technology assessments of orphan drugs in Germany from January 2011 to December 2023.
Potential Biases
Potential bias due to the lack of standard care comparisons in limited assessments.
Limitations
The study may not fully capture all orphan drugs or their effects due to the limited assessments and lack of comparative data.
Participant Demographics
Orphan drugs evaluated were for various rare diseases, but specific demographics were not detailed.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website